NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

溶瘤病毒治療劑的全球市場(2020-2030):市場預測(銷售的藥物,管道藥物,病毒,應用,地區(15個國家)),競爭分析

Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 1000070
出版日期 內容資訊 英文 179 Pages
商品交期: 最快1-2個工作天內
價格
溶瘤病毒治療劑的全球市場(2020-2030):市場預測(銷售的藥物,管道藥物,病毒,應用,地區(15個國家)),競爭分析 Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
出版日期: 2021年04月09日內容資訊: 英文 179 Pages
簡介

在預測期內,溶瘤病毒的全球市場預計將以26.28%的複合年增長率增長,到2030年將增長至6.92億美元。

癌症病例增加,臨床試驗增加,研究費用增加以及採用無機增長等因素正在推動市場的增長。另一方面,仍然需要解決一些重要的問題以促進未來的增長,例如治療藥物的總成本高和缺乏針對特定藥物的檢測方法。

本報告探討了全球溶瘤病毒市場,定義和概述了市場,分析了新的冠狀病毒感染(COVID-19)和其他市場影響因素,並進行了規範和補償,總結了環境,市場規模的變化/預測,按細分類別細分,例如上市藥品/開發階段/病毒/用途/地區/主要國家/地區,競爭環境,主要公司的概況等。

執行摘要

第1章產品定義

第2章市場範圍

第3章調查方法

第4章市場概述

  • 市場定義
  • 溶瘤病毒治療劑在癌症治療中的重要性
  • 市場規模/增長潛力
  • COVID-19的影響

第5章工業考慮

  • 概述
  • 監管情況
  • 法律要求/框架:美國
  • 法律要求/框架:歐洲
  • 法律要求/框架:亞太地區
  • 全球快速通道批准規定
  • 兌換場景
  • 專利分析

第6章市場動態

  • 概述
  • 影響分析
  • 市場驅動力
  • 市場約束因素
  • 市場機會

第7章競爭情況

  • 聯盟/合作
  • 業務擴展
  • 產品發佈/產品更新
  • 併購
  • 市場份額分析
  • 增長份額分析

第8章流行病學分析

第9章市場分析/預測:按投放的毒品分類

  • 概述
  • 意境
  • Oncorine
  • 裡維

第10章市場分析/預測:處於開發階段

  • 概述
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第11章市場分析/預測:按病毒

  • 概述
  • 轉基因溶瘤病毒
    • 單純皰疹病毒(HSV)
    • 腺病毒
    • 牛痘病毒
  • 溶瘤野生株病毒
    • 獅子病毒
    • 新城疫病毒(NDV)
    • 大皰性口炎病毒(VSV)

第12章市場分析/預測:按應用

  • 概述
  • 實體瘤
    • 乳腺癌
    • 前列腺癌
    • 肺癌
    • 膠質母細胞瘤
    • 黑色素瘤
    • 其他
  • 血液系統惡性腫瘤
    • 淋巴瘤
    • 白血病
    • 骨髓瘤

第13章市場分析/預測:按地區/主要國家/地區

  • 北美
    • 美國
  • 歐洲
    • 英國
    • 拉脫維亞
    • 佐治亞州
    • 亞美尼亞
    • 德國
    • 法國
    • 意大利
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 其他

第14章公司簡介

  • Amgen Inc.
  • DAIICHI SANKYO COMPANY, LIMITED
  • DNAtrix
  • Genelux
  • Oncolytics Biotech, Inc.
  • PsiOxus Therapeutics
  • RIGVIR Ltd.
  • Shanghai Sunway Biotech Co., Ltd.,
  • SillaJen, Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Transgene sa
  • VCNBiosciences
  • ViroCure
  • Viralytics Ltd. (Merck & Co., Inc.)
目錄
Product Code: BHP1031SA

"Global Oncolytic Virus Therapies Market to Reach $962.0 Million by 2030."

Market Report Coverage - Oncolytic Virus Therapies

Market Segmentation

  • Commercialized Therapies: Imlygic, Oncorine, and RIGVIR
  • Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV
  • Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)
  • Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)

Regional Segmentation

  • North America: U.S.
  • Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)
  • Asia-Pacific: Japan, China, Rest-of-APAC (India, Australia, South Korea)

Growth Drivers

  • Increasing Incidence of Cancer
  • Rising Number of Clinical Trials
  • Increasing Research Funding from National Cancer Institute
  • Increasing Adoption of Inorganic Growth Strategies in the Market

Market Challenges

  • High Cost of Therapy
  • Lack of Therapy-Specific Assays

Market Opportunities

  • Opportunities in the Emerging Economies
  • Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
  • What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
  • How is each segment of the market expected to grow during the forecast period 2020-2030?
  • Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
  • What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?
  • What is the COVID-19 impact on the global oncolytic virus therapies market?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
  • What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?
  • What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
  • How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types:
    • Commercialized Therapies
    • Pipeline Therapies
    • Type of Virus
    • Application
    • Region

Market Overview

Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature's material (virus) to find and destroy malignant cells. Oncolytic virus therapy is "a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person's genes". Oncolytic virotherapy is a form of gene therapy that used nature's material (virus) to find and destroy malignant cells.

Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.

Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.

Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Oncolytic Virus Therapies Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment
  • 4.3 Market Size and Growth Potential, $Million, 2019-2030
  • 4.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market

5 Industry Insights

  • 5.1 Overview
  • 5.2 Regulatory Scenario
  • 5.3 Legal Requirements and Framework in the U.S
    • 5.3.1 Clinical Trial Authorization
    • 5.3.2 U.S. FDA Guidelines for BLA Submission
  • 5.4 Legal Requirements and Framework in Europe
    • 5.4.1 EMA Biologics License Application Process
    • 5.4.2 Centralized Procedure
    • 5.4.3 Decentralized Procedure
    • 5.4.4 Mutual-Recognition Procedure
  • 5.5 Legal Requirements and Framework in Asia-Pacific
    • 5.5.1 China
    • 5.5.2 Japan
  • 5.6 Expedited Regulatory Designations Around the World
  • 5.7 Reimbursement Scenario
  • 5.8 Patent Analysis
    • 5.8.1 Patent Filing Trend

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Increasing Incidence of Cancer
    • 6.3.2 Rising Number of Clinical Trials
    • 6.3.3 Increasing Research Funding from National Cancer Institute
    • 6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market
  • 6.4 Market Restrains
    • 6.4.1 High Cost of Therapy
    • 6.4.2 Lack of Therapy-Specific Assays
  • 6.5 Market Opportunities
    • 6.5.1 Opportunities in the Emerging Economies
    • 6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

7 Competitive Landscape

  • 7.1 Synergistic Activities
  • 7.2 Business Expansion Activities and Others
  • 7.3 Product Launches and Product Updates
  • 7.4 Mergers and Acquisitions
  • 7.5 Market Share Analysis
  • 7.6 Growth Share Analysis
    • 7.6.1 Growth Share Analysis (by Commercialized Therapy)

8 Oncolytic Virus Therapies: Epidemiology Analysis

9 Global Oncolytic Virus Therapies Market (by Commercialized Therapies), $Million, 2019-2030

  • 9.1 Overview
  • 9.2 Imlygic
  • 9.3 Oncorine
  • 9.4 RIGVIR

10 Global Oncolytic Virus Therapies Market (by Pipeline Therapies), $Million, 2019-2030

  • 10.1 Overview
  • 10.2 Phase I
  • 10.3 Phase II
  • 10.4 Phase III
  • 10.5 Phase IV

11 Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030

  • 11.1 Overview
  • 11.2 Genetically Engineered Oncolytic Virus
    • 11.2.1 Herpes Simplex Virus (HSV)
    • 11.2.2 Adenovirus
    • 11.2.3 Vaccinia Virus
  • 11.3 Oncolytic Wild-Type Virus
    • 11.3.1 Reovirus (Respiratory Enteric Orphan Virus)
    • 11.3.2 Newcastle Disease Virus (NDV)
    • 11.3.3 Vesicular Stomatitis Virus (VSV)

12 Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030

  • 12.1 Overview
  • 12.2 Solid Tumor
    • 12.2.1 Breast Cancer
    • 12.2.2 Prostate Cancer
    • 12.2.3 Lung Cancer
    • 12.2.4 Glioblastoma
    • 12.2.5 Melanoma
    • 12.2.6 Other Applications
  • 12.3 Hematological Malignancies
    • 12.3.1 Lymphoma
    • 12.3.2 Leukemia
    • 12.3.3 Myeloma

13 Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
  • 13.3 Europe
    • 13.3.1 U.K.
    • 13.3.2 Latvia
    • 13.3.3 Georgia
    • 13.3.4 Armenia
    • 13.3.5 Germany
    • 13.3.6 France
    • 13.3.7 Italy
    • 13.3.8 Rest-of-Europe
  • 13.4 Asia-Pacific
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 Rest-of-APAC

14 Company Profiles

  • 14.1 Overview
  • 14.2 Amgen Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights about Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 DAIICHI SANKYO COMPANY, LIMITED
    • 14.3.1 Company Overview
    • 14.3.2 Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights About Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 DNAtrix
    • 14.4.1 Company Overview
    • 14.4.2 Role of DNAtrix in the Global Oncolytic Virus Therapies Market
    • 14.4.3 SWOT Analysis
  • 14.5 Genelux
    • 14.5.1 Company Overview
    • 14.5.2 Role of Genelux in the Global Oncolytic Virus Therapies Market
    • 14.5.3 SWOT Analysis
  • 14.6 Oncolytics Biotech, Inc.
    • 14.6.1 Company Overview
    • 14.6.2 Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market
    • 14.6.3 Financials
    • 14.6.4 SWOT Analysis
  • 14.7 PsiOxus Therapeutics
    • 14.7.1 Company Overview
    • 14.7.2 Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market
    • 14.7.3 SWOT Analysis
  • 14.8 RIGVIR Ltd.
    • 14.8.1 Company Overview
    • 14.8.2 Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market
    • 14.8.3 SWOT Analysis
  • 14.9 Shanghai Sunway Biotech Co., Ltd.,
    • 14.9.1 Company Overview
    • 14.9.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market
    • 14.9.3 SWOT Analysis
  • 14.1 SillaJen, Inc.
    • 14.10.1 Company Overview
    • 14.10.2 Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market
    • 14.10.3 SWOT Analysis
  • 14.11 Sorrento Therapeutics, Inc.
    • 14.11.1 Company Overview
    • 14.11.2 Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market
    • 14.11.3 Financials
    • 14.11.4 Key Insights About Financial Health of the Company
    • 14.11.5 SWOT Analysis
  • 14.12 Takara Bio Inc.
    • 14.12.1 Company Overview
    • 14.12.2 Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market
    • 14.12.3 Financials
    • 14.12.4 Key Insights About Financial Health of the Company
    • 14.12.5 SWOT Analysis
  • 14.13 Transgene sa
    • 14.13.1 Company Overview
    • 14.13.2 Role of Transgene sa in the Global Oncolytic Virus Therapies Market
    • 14.13.3 Financials
    • 14.13.4 SWOT Analysis
  • 14.14 VCNBiosciences
    • 14.14.1 Company Overview
    • 14.14.2 Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market
    • 14.14.3 SWOT Analysis
  • 14.15 ViroCure
    • 14.15.1 Company Overview
    • 14.15.2 Role of ViroCure in the Global Oncolytic Virus Therapies Market
    • 14.15.3 SWOT Analysis
  • 14.16 Viralytics Ltd. (Merck & Co., Inc.)
    • 14.16.1 Company Overview
    • 14.16.2 Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market
    • 14.16.3 Financials
    • 14.16.4 Key Insights About Financial Health of the Company
    • 14.16.5 SWOT Analysis

List of Tables

  • Table 5.1: Regulatory Scenario Across the World
  • Table 5.2: Expedited Regulatory Designations Around the World
  • Table 5.3: Key Market Access Landscape (by Country), January 2019
  • Table 9.1: Commercialized Therapies
  • Table 10.1: Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020
  • Table 10.2: Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020
  • Table 10.3: Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020
  • Table 11.1: Key Herpes Simplex Virus (HSV)-Based Oncolytic Therapies
  • Table 11.2: Key Adenovirus-Based Oncolytic Therapies
  • Table 11.3: Key Vaccinia Virus-Based Oncolytic Therapies
  • Table 11.4: Key Reovirus-Based Oncolytic Therapies
  • Table 13.1: Rest-of-APAC - Pipeline Drugs

List of Figures

  • Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies Market
  • Figure 3: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019 Vs. 2030
  • Figure 4: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019 vs. 2030
  • Figure 5: Global Oncolytic Virus Therapies Market Snapshot, $Million, 2019 and 2030
  • Figure 2.1: Global Oncolytic Virus Therapies Market Segmentation
  • Figure 3.1: Global Oncolytic Virus Therapies Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 4.2: Global Oncolytic Virus Therapies Market: COVID-19 Impact
  • Figure 5.1: Clinical Trial Authorization for Oncolytic Virus Therapies
  • Figure 5.2: Steps for Obtaining Marketing Authorization
  • Figure 5.3: U.S. FDA Expedited Review Programs
  • Figure 5.4: Regulatory Strategy for Oncolytic Virus Therapies in the U.S.
  • Figure 5.5: U.S.FDA Review Timeline
  • Figure 5.6: Regulatory Strategy for Oncolytic Virus Therapies in Europe
  • Figure 5.7: EMA Review Timeline
  • Figure 5.9: Overview of PMDA and MLHW Drug Approval Process in Japan
  • Figure 5.10: Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021
  • Figure 6.1: Impact Analysis
  • Figure 6.2: Cancer Cases Projection, 2016-2020
  • Figure 6.3: Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019
  • Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
  • Figure 6.5: NCI Fiscal Budget Year-on-Year, 2013-2018
  • Figure 6.6: Synergistic Activities, 2018-2020
  • Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
  • Figure 7.2: Synergistic Activities Share (by Company), January 2018-March 2021
  • Figure 7.3: Business Expansion Activities Share (by Company), January 2018-March 2021
  • Figure 7.4: Number of Product Launches (by Company), January 2018-March 2021
  • Figure 7.5: Mergers and Acquisitions, January 2018-March 2021
  • Figure 7.6: Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), $Million, 2020
  • Figure 7.7: Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020
  • Figure 8.1: Type of Cancer
  • Figure 8.2: Global Estimated Percent of New Cancer Cases (by Sex), 2030
  • Figure 8.3: Expected Cancer Cases in the World (by Country), 2030
  • Figure 8.4: Relative Number of Expected New Cancer Cases (by Country), 2030
  • Figure 9.1: Global Oncolytic Virus Therapies Market (Imlygic), $Million, 2019-2030
  • Figure 9.2: Global Oncolytic Virus Therapies Market (Oncorine), $Million, 2019-2030
  • Figure 9.3: Global Oncolytic Virus Therapies Market (RIGVIR), $Million, 2019-2030
  • Figure 10.1: Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019
  • Figure 11.1: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
  • Figure 11.2: Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), $Million, 2019 and 2030
  • Figure 11.3: Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), $Million, 2019-2030
  • Figure 11.4: Global Oncolytic Virus Therapies Market (Adenovirus), $Million, 2019-2030
  • Figure 11.5: Global Oncolytic Virus Therapies Market (Vaccinia Virus), $Million, 2019-2030
  • Figure 11.6: Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), $Million, 2019 and 2030
  • Figure 11.7: Global Oncolytic Virus Therapies Market (Reovirus), $Million, 2019-2030
  • Figure 11.8: Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), $Million, 2019-2030
  • Figure 11.9: Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), $Million, 2019-2030
  • Figure 12.1: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
  • Figure 12.2: Global Oncolytic Virus Therapies Market (by Solid Tumor), $Million, 2019 and 2030
  • Figure 12.3: Global Oncolytic Virus Therapies Market (Breast Cancer), $Million, 2019-2030
  • Figure 12.4: Global Oncolytic Virus Therapies Market (Prostate Cancer), $Million, 2019-2030
  • Figure 12.5: Global Oncolytic Virus Therapies Market (Lung Cancer), $Million, 2019-2030
  • Figure 12.6: Global Oncolytic Virus Therapies Market (Glioblastoma), $Million, 2019-2030
  • Figure 12.7: Global Oncolytic Virus Therapies Market (Melanoma), $Million, 2019-2030
  • Figure 12.8: Global Oncolytic Virus Therapies Market (Other Applications), $Million, 2019-2030
  • Figure 12.9: Global Oncolytic Virus Therapies Market (by Haematological Malignancies), $Million, 2019 and 2030
  • Figure 12.10: Global Oncolytic Virus Therapies Market (Lymphoma), $Million, 2019-2030
  • Figure 12.11: Global Oncolytic Virus Therapies Market (Leukemia), $Million, 2019-2030
  • Figure 12.12: Global Oncolytic Virus Therapies Market (Myeloma), $Million, 2019-2030
  • Figure 13.1: Global Oncolytic Virus Therapies Market (by Region), 2019-2030
  • Figure 13.2: Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
  • Figure 13.3: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2019
  • Figure 13.4: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2030
  • Figure 13.5: North America Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.6: North America: Market Dynamics
  • Figure 13.7: U.S. Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.8: Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.9: Europe: Market Dynamics
  • Figure 13.10: Europe Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
  • Figure 13.11: U.K. Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.12: Latvia Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.13: Georgia Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.14: Armenia Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.15: Germany Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.16: France Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.17: Italy Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.18: Rest-of-Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.19: Asia-Pacific Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.20: APAC: Market Dynamics
  • Figure 13.21: APAC Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
  • Figure 13.22: China Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.23: Japan Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 13.24: RoAPAC Oncolytic Virus Therapies Market, $Million, 2019-2030
  • Figure 14.1: Total Number of Companies Profiled
  • Figure 14.2: Amgen Inc.: Product Portfolio
  • Figure 14.3: Amgen Inc.: Overall Financials, $Million, 2018-2020
  • Figure 14.4: Amgen Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 14.5: Amgen Inc. R&D Expenditure, $Billion, 2018-2020
  • Figure 14.6: Amgen Inc.: SWOT Analysis
  • Figure 14.7: DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio
  • Figure 14.8: DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, $Billion, 2017-2019
  • Figure 14.9: Amgen Inc. R&D Expenditure, $Billion, 2017-2019
  • Figure 14.10: DAIICHI SANKYO COMPANY, LIMITED: SWOT Analysis
  • Figure 14.11: DNAtrix: Product Portfolio
  • Figure 14.12: DNAtrix: SWOT Analysis
  • Figure 14.13: Genelux: Product Portfolio
  • Figure 14.14: Genelux: SWOT Analysis
  • Figure 14.15: Oncolytics Biotech, Inc.: Product Portfolio
  • Figure 14.16: Oncolytics Biotech, Inc.: SWOT Analysis
  • Figure 14.17: PsiOxus Therapeutics: Pipeline Product Portfolio
  • Figure 14.18: PsiOxus Therapeutics: SWOT Analysis
  • Figure 14.19: RIGVIR Ltd.: Overall Service Portfolio
  • Figure 14.20: RIGVIR Ltd.: SWOT Analysis
  • Figure 14.21: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
  • Figure 14.22: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
  • Figure 14.23: SillaJen, Inc.: Product Portfolio
  • Figure 14.24: SillaJen, Inc.: SWOT Analysis
  • Figure 14.25: Sorrento Therapeutics, Inc.: Product Portfolio
  • Figure 14.26: Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019
  • Figure 14.27: Sorrento Therapeutics, Inc. R&D Expenditure, $Million, 2017-2019
  • Figure 14.28: Sorrento Therapeutics, Inc.: SWOT Analysis
  • Figure 14.29: Takara Bio Inc.: Product Portfolio
  • Figure 14.30: Takara Bio Inc.: Overall Financials, 2017-2019
  • Figure 14.31: Takara Bio Inc.: Revenue (by Segment), $Million, 2017-2019
  • Figure 14.32: Takara Bio Inc.: Revenue (by Region), $Million, 2017-2019
  • Figure 14.33: Takara Bio Inc.: R&D Expenditure, 2017-2019
  • Figure 14.34: Takara Bio Inc.: SWOT Analysis
  • Figure 14.35: Transgene sa: Product Portfolio
  • Figure 14.36: Transgene sa: Overall Financials, $Million, 2017-2019
  • Figure 14.37: Transgene sa: SWOT Analysis
  • Figure 14.38: VCNBiosciences: Pipeline Product Portfolio
  • Figure 14.39: VCNBiosciences: SWOT Analysis
  • Figure 14.40: ViroCure: Product Portfolio
  • Figure 14.41: ViroCure: SWOT Analysis
  • Figure 14.42: Viralytics Ltd., (Merck & Co., Inc.): Product Portfolio
  • Figure 14.43: Merck & Co., Inc.: Overall Financials, $Million, 2018-2020
  • Figure 14.44: Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 14.45: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 14.46: Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 14.47: Merck & Co., Inc.: SWOT Analysis